Letter to the Editor
Post-market drug safety evidence sources: an analysis of FDA drug safety communications
- Ms. Ishiguro conducted this research when she was a visiting scientist in the Office of Surveillance and Epidemiology, CDER, FDA in 2010.
G. A. Neyarapally, PharmD, MPH, Interdisciplinary Scientist, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Building 22, Room 4461, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. E-mail: George.email@example.com
No abstract is available for this article.